Medexus Pharmaceuticals (TSE:MDP) Lifted to “Strong-Buy” at Ventum Cap Mkts

Ventum Cap Mkts upgraded shares of Medexus Pharmaceuticals (TSE:MDP) to a strong-buy rating in a research note published on Wednesday morning, Zacks.com reports.

Medexus Pharmaceuticals Stock Performance

Shares of TSE MDP opened at C$1.82 on Wednesday. The stock has a fifty day moving average price of C$1.67 and a two-hundred day moving average price of C$1.88. The firm has a market cap of C$44.52 million, a P/E ratio of 4.55 and a beta of 1.82. Medexus Pharmaceuticals has a 1 year low of C$1.44 and a 1 year high of C$3.53.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.